Читать книгу Diagnóstico y tratamiento de la infección por el virus de la inmunodeficiencia humana, Infecciones oportunistas y trastornos relacionados - Rosa Nohemí Terán Terán - Страница 12

BIBLIOGRAFÍA

1.Jens, D. Lundgren AG, Babiker, Fred Gordin, Sean Emery B, Grund, Shweta Sharmaet al., STARTof the I. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807.

2.Rockstroh JK. Major Clinical Outcomes in Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study. J Infect Dis [Internet]. 2008;197(8):1133–44. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1086/586713

3.Mari M. Kitahata, Stephen J. Gange, Alison G. Abraham, Barry Merriman MSS et al. New England Journal. N Engl J Med. 2009;360(18):360:1815-26.

4.The TEMPRANO ANRS 12136. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med [Internet]. 2015;373(9):808–22. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1507198

5.Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic Review of HIV Transmission between Heterosexual Serodiscordant Couples where the HIV-Positive Partner Is Fully Suppressed on Antiretroviral Therapy. PLoS One. 2013;8(2).

6.Cohen, Myron S, Ying Q Chen, Marybeth MacCauley, Theresa Gamble MH et al. Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal. New Engl J. 2011;365(6):365:493-505.

7.Florencia Pereyra, M.D.*, Janet Lo, M.D., M.MSc.*, Virginia A. Triant, M.D., M.P.H., Jeffrey Wei, B.A., Maria J. Buzon, Ph.D., Kathleen V. Fitch, MSN, Janice Hwang, M.D., Jennifer H. Campbell, B.S., Tricia H. Burdo, Ph.D., Kenneth C. Williams, Ph.D., Suhn MD. Increased Coronary Atherosclerosis and Immune Activation in HIV-1 Elite Controllers. AIDS2012 Novemb. 2013;26(18):2409–12.

8.Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med [Internet]. 2006;354(3):251–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16421366%5Cnhttp://www.nejm.org/doi/full/10.1056/nejmoa051871%5CnAll Papers/G/Gallant et al. 2006 - Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.pdf

9.Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results. J Infect Dis. 2011;204(8):1191–201.

10.Post F a, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49–57.

11.Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, et al. A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for initial HIV-1 Treatment: Week 96 results. J Acquir Immune Defic Syndr [Internet]. 2016;72(1):58–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26829661

12.Beltran Carlos, editor. Estándares para el diagnóstico y tratamiento del VIH/SIDA en Latinoamérica. primera. Quito; 2017. 306 p.

13.Amin J, Becker S, Belloso W, Boffito M, Cooper D, Crabtree-Ramirez B, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;

14.Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: An analysis of trial data. Ann Intern Med. 2014;161(1):1–10.

15.Kryst J, Kawalec P, Pilc A. Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: A systematic review and meta-analysis of randomized controlled trials. Vol. 10, PLoS ONE. 2015.

16.Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M-A, et al. Brief Report. JAIDS J Acquir Immune Defic Syndr. 2015;

17.Molina J-M, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014;17 (4 Suppl 3):19490.

18.Cruciani M, Malena M. Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: Clinical utility and patient considerations. Patient Prefer Adherence. 2015;9:299–310.

19.Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–35.

20.Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. Aids [Internet]. 2015;29(2):167–74. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002030-201501140-00004

21.Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric Symptoms in Patients Receiving Dolutegravir. JAIDS J Acquir Immune Defic Syndr [Internet]. 2016;74(4):1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-900000000-97064

22.Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: A systematic review. PLoS One. 2016;11(10):1–13.

23.Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks. Clin Drug Investig. 2015;35(3):211–9.

24.Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–16.

25.Rockstroh J, DeJesus E, Saag M, Yazdanpanah Y, Lennox JL, Wan H, et al. Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naive HIV-1-infected patients: final 5-year double-blind results from STARTMRK. AIDS 2012 XIX Int AIDS Conf Washington, DC, USA July 22-27, 2012. 2012;Poster# LBPE19.

26.Arathoon E, Schneider S, Baraldi E, Lim PL, Opravil M, Van De Casteele T, et al. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Int J STD AIDS [Internet]. 2013;24(1):12–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23440570

27.Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Aids [Internet]. 2008;22(12):1389–97. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002030-200807310-00001

28.Orrell C, Hagins D, Belonosova E, Porteiro N, Walmsley S, Falcó V, et al. Superior Efficacy of Dolutegravir / Abacavir / Lamivudine Fixed Dose Combination Compared With Ritonavir Boosted Atazanavir Plus Tenofovir / Emtricitabine in Treatment-Naive Women With HIV-1 Infection ( ARIA Study ). 2016;2016.

29.Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food. JAIDS J Acquir Immune Defic Syndr [Internet]. 2014;66(4):393–8. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-201408010-00007

30.Zolopa AR, Andersen J, Komarow L, Sanne I, Sanchez A, Hogg E, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One. 2009;4(5).

31.Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV [Internet]. 2016;3(9):e410–20. Available from: http://dx.doi.org/10.1016/S2352-3018(16)30016-9

32.Rockstroh JK, DeJesus E, Henry K, Molina J-M, Gathe J, Ramanathan S, et al. A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection. JAIDS J Acquir Immune Defic Syndr [Internet]. 2013;62(5):483–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-201304150-00002

33.Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, Mccomsey GA, Godfrey C, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60(12):1842–51.

34.Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510–20.

35.Mark Wainberg M. The Absence of Drug Resistance against Dolutegravir in First-Line Therapy is Attributable to Reduced Viral Replicative Fitness. JAIDS J Acquir Immune Defic Syndr. 2017;74(p 66):1–101.

36.LiYang, QiLi L-B-Q. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. Int J Antimicrob Agents. 2019;54(5):547–55.

37.Wainberg MM. I-103 The absence of drug resistance against dolutegravir in first-line therapy is attributable to reduced viral replicative fitness. JAIDS J Acquir Immune Defic Syndr. 2017;74(66):I–103.

38.Zash, Rebecca, Joseph Makhema RS. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception Rebecca. N Engl J Med. 379(10):979–81.

39.Zash R, Homes L., Diseko M. JD et al. Neural-tube defects and Antiretroviral treatment Regímenes in Botswana. N Engl J Med. 2019;391(9):827–40.

40.Zash R, Homes L., Diseko M. JD et al. MOAX0105LB - Oral Abstract. IAS 2019. Mexico: IAS 2019; 2019. p. 105.

41.Raesima M. et al. Dolutegravir Use at Conception — Additional Surveillance Data from Botswana. N Engl J Med. 381(9):885–7.

42.Pereira G. et. No ocurrences of neural tube defectos among 382 women on dolutegravir at pregnacy. Abstract. Mexico IAS 2019; 2019. p. Abstract MOAX0104LB.

43.The World Health Organisation. WHO. Statement on DTG - Geneva. Geneve; 2018. p. 1–2.

44.World Health Organization (WHO). Update of first and second line antiretroviral regimens. Who. 2019;(July).

45.Society EACS. Guidelines. Version 10.0 November 2019. London: 2019; 2019. p. 0–122.

46.AIDSinfo. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Dep Heal Hum Serv [Internet]. 2018;298. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf

47.Antiviral Society- USA Panel. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA - J Am Med Assoc. 2018;320(4):379–96.

48.Cahn P, Rolón MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20(1):1–7.

49.Cahn Pet al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovirdisoproxilfumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiorit. Lancet 2019. 2019;393(10167):143–55.

50.Cento V PC. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety. J Glob Antimicrob Resist.